ESSA Pharma Inc. financial data

Symbol
EPIX
Location
Vancouver
Fiscal year end
30 September
Latest financial report
10-Q - Q2 2025 - 13 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4614% % 21%
Debt-to-equity 2.3% % -18%
Return On Equity -22% % -7.5%
Return On Assets -21% % -8.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47,308,394 shares 6.6%
Common Stock, Shares, Outstanding 44,388,550 shares 0.04%
Entity Public Float $376,600,000 USD 378%
Common Stock, Value, Issued $279,862,420 USD 0.04%
Weighted Average Number of Shares Outstanding, Basic 44,388,550 shares 0.05%
Weighted Average Number of Shares Outstanding, Diluted 44,388,550 shares 0.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $18,610,662 USD -19%
General and Administrative Expense $17,043,170 USD 47%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $7,233,747 USD 0.89%
Net Income (Loss) Attributable to Parent $25,265,209 USD 8.7%
Earnings Per Share, Basic 0 USD/shares 9.7%
Earnings Per Share, Diluted -0.09 USD/shares 44%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $85,952,587 USD -0.04%
Assets, Current $110,502,100 USD -16%
Operating Lease, Right-of-Use Asset $0 USD -100%
Assets $110,502,100 USD -17%
Accounts Payable, Current $971,372 USD -49%
Accrued Liabilities, Current $454,231 USD -48%
Liabilities, Current $1,599,955 USD -55%
Operating Lease, Liability, Noncurrent $154,289 USD -39%
Liabilities $1,599,955 USD -58%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,097,007 USD 0.16%
Retained Earnings (Accumulated Deficit) $226,914,172 USD -13%
Stockholders' Equity Attributable to Parent $108,902,145 USD -15%
Liabilities and Equity $110,502,100 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,469,999 USD 4.7%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $3,928,649 USD -148%
Common Stock, Shares, Issued 44,388,550 shares 0.04%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,398,648 USD -733%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85,952,587 USD -0.04%
Deferred Tax Assets, Valuation Allowance $50,262,000 USD 11%
Deferred Tax Assets, Gross $50,262,000 USD 11%
Operating Lease, Liability $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $25,261,849 USD 8.6%
Lessee, Operating Lease, Liability, to be Paid $313,974 USD -25%
Operating Lease, Liability, Current $125,912 USD 25%
Lessee, Operating Lease, Liability, to be Paid, Year Two $135,869 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $131,912 USD 24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $33,773 USD -49%
Lessee, Operating Lease, Liability, to be Paid, Year Three $46,193 USD -66%
Deferred Tax Assets, Operating Loss Carryforwards $49,750,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Four $11,719 USD
Additional Paid in Capital $58,050,904 USD 9.8%
Deferred Tax Assets, Net of Valuation Allowance $0 USD